![]() ![]() ![]() Of 510 MCI participants, 352 were from ADNI (43.5% females mean age, 71.68 years), and 158 from MEMENTO (46.2% females 68.98 years). Cohorts were analyzed separately for: 1) cross-sectional associations between NPS status and ATN biomarkers (linear regressions) 2) 4-year longitudinal repeated-measures associations of MBI and NPSnotMBI with ATN biomarkers (hierarchical linear mixed-effects models-LMEs) and 3) rates of incident dementia (Cox proportional hazards regressions). ![]() Exposure was based on three-group stratification: 1) NPS meeting MBI criteria 2) conventionally measured NPS (NPSnotMBI) and 3) noNPS. Methodsĭata were from two independent referral-based cohorts, ADNI (mean follow-up 3.14 years) and MEMENTO (4.25 years), collected 2003–2021. Here, to determine if adding MBI would better identify AD, we interrogated associations between MBI in MCI, and cerebrospinal fluid biomarkers, cross-sectionally and longitudinally. Adding MBI to MCI improves dementia prognostication over conventional approaches of incorporating neuropsychiatric symptoms (NPS). Mild cognitive impairment (MCI) leverages cognitive decline to identify the risk group similarly, mild behavioral impairment (MBI) leverages behavioral change. Disease-modifying drug use necessitates better Alzheimer disease (AD) detection. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |